{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:22:40Z","timestamp":1794561760503,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to evaluate the role of crizotinib in rare tumors that harbored either <jats:italic>ALK<\/jats:italic> or <jats:italic>ROS1<\/jats:italic> rearrangements. Patients with malignancies that progressed following at least one prior systemic therapy were accrued to the NCI-MATCH for molecular profiling, and those with actionable <jats:italic>ALK<\/jats:italic> or <jats:italic>ROS1<\/jats:italic> rearrangements were offered participation in sub-protocols F or G, respectively. There were five patients who enrolled on Arm F (ALK) and four patients on Arm G (ROS1). Few grade 3 or 4 toxicities were noted, including liver test abnormalities, and acute kidney injury. For sub-protocol F (ALK), the response rate was 50% (90% CI 9.8\u201390.2%) with one complete response among the 4 eligible patients. The median PFS was 3.8 months, and median OS was 4.3 months. For sub-protocol G (ROS1) the response rate was 25% (90% CI 1.3\u201375.1%). The median PFS was 4.3 months, and median OS 6.2 months. Data from 3 commercial vendors showed that the prevalence of <jats:italic>ALK<\/jats:italic> and <jats:italic>ROS1<\/jats:italic> rearrangements in histologies other than non-small cell lung cancer and lymphoma was rare (0.1% and 0.4% respectively). We observed responses to crizotinib which met the primary endpoint for <jats:italic>ALK<\/jats:italic> fusions, albeit in a small number of patients. Despite the limited accrual, some of the patients with these oncogenic fusions can respond to crizotinib which may have a therapeutic role in this setting.<\/jats:p>","DOI":"10.1038\/s41698-022-00256-w","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T11:03:01Z","timestamp":1646132581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9483-6903","authenticated-orcid":false,"given":"A. S.","family":"Mansfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9234-3497","authenticated-orcid":false,"given":"Z.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. T.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4852-4642","authenticated-orcid":false,"given":"C. H.","family":"Lieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-6344","authenticated-orcid":false,"given":"P. M.","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6806-9061","authenticated-orcid":false,"given":"A. E.","family":"Drilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. P.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Takebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1881-4451","authenticated-orcid":false,"given":"D.","family":"Hovelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tomlins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Poorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5724-4917","authenticated-orcid":false,"given":"R. J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. M.","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9720-9737","authenticated-orcid":false,"given":"L. V.","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3855-0166","authenticated-orcid":false,"given":"D.","family":"Patton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3309-5988","authenticated-orcid":false,"given":"P. M.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. R.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. A.","family":"Conley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. L.","family":"Arteaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. N.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J.","family":"O\u2019Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. P.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. T.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"256_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/clpt.2013.200","volume":"95","author":"B Solomon","year":"2014","unstructured":"Solomon, B., Wilner, K. D. & Shaw, A. T. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clin. Pharm. Ther. 95, 15\u201323 (2014).","journal-title":"Clin. Pharm. Ther."},{"key":"256_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1097\/JTO.0b013e3181c4dedb","volume":"4","author":"B Solomon","year":"2009","unstructured":"Solomon, B., Varella-Garcia, M. & Camidge, D. R. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J. Thorac. Oncol. 4, 1450\u20131454 (2009).","journal-title":"J. Thorac. Oncol."},{"key":"256_CR3","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-07-6158","volume":"68","author":"YL Choi","year":"2008","unstructured":"Choi, Y. L. et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 68, 4971\u20134976 (2008).","journal-title":"Cancer Res."},{"key":"256_CR4","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-08-3248","volume":"15","author":"K Takeuchi","year":"2009","unstructured":"Takeuchi, K. et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 15, 3143\u20133149 (2009).","journal-title":"Clin. Cancer Res."},{"key":"256_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1517\/13543784.2015.979284","volume":"24","author":"G Bronte","year":"2015","unstructured":"Bronte, G. et al. Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy. Expert Opin. Investig. Drugs 24, 125\u2013132 (2015).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"256_CR6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nrc3612","volume":"13","author":"AT Shaw","year":"2013","unstructured":"Shaw, A. T., Hsu, P. P., Awad, M. M. & Engelman, J. A. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat. Rev. Cancer 13, 772\u2013787 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"256_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4116","volume":"5","author":"T Wiesner","year":"2014","unstructured":"Wiesner, T. et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat. Commun. 5, 3116 (2014).","journal-title":"Nat. Commun."},{"key":"256_CR8","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-12-2851","volume":"19","author":"KD Davies","year":"2013","unstructured":"Davies, K. D. & Doebele, R. C. Molecular pathways: ROS1 fusion proteins in cancer. Clin. Cancer Res. 19, 4040\u20134045 (2013).","journal-title":"Clin. Cancer Res."},{"key":"256_CR9","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","volume":"371","author":"AT Shaw","year":"2014","unstructured":"Shaw, A. T. et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 371, 1963\u20131971 (2014).","journal-title":"N. Engl. J. Med."},{"key":"256_CR10","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/JTO.0b013e3182570919","volume":"7","author":"H Yasuda","year":"2012","unstructured":"Yasuda, H., de Figueiredo-Pontes, L. L., Kobayashi, S. & Costa, D. B. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J. Thorac. Oncol. 7, 1086\u20131090 (2012).","journal-title":"J. Thorac. Oncol."},{"key":"256_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.leukres.2013.01.014","volume":"37","author":"D Cilloni","year":"2013","unstructured":"Cilloni, D. et al. Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. Leuk. Res. 37, 520\u2013530 (2013).","journal-title":"Leuk. Res."},{"key":"256_CR12","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/cncr.27967","volume":"119","author":"J Lee","year":"2013","unstructured":"Lee, J. et al. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer 119, 1627\u20131635 (2013).","journal-title":"Cancer"},{"key":"256_CR13","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","volume":"14","author":"YP Mosse","year":"2013","unstructured":"Mosse, Y. P. et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children\u2019s Oncology Group phase 1 consortium study. Lancet Oncol. 14, 472\u2013480 (2013).","journal-title":"Lancet Oncol."},{"key":"256_CR14","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","volume":"35","author":"YP Mosse","year":"2017","unstructured":"Mosse, Y. P. et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children\u2019s oncology group study. J. Clin. Oncol. 35, 3215\u20133221 (2017).","journal-title":"J. Clin. Oncol."},{"key":"256_CR15","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","volume":"363","author":"JE Butrynski","year":"2010","unstructured":"Butrynski, J. E. et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363, 1727\u20131733 (2010).","journal-title":"N. Engl. J. Med."},{"key":"256_CR16","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1158\/2159-8290.CD-14-0377","volume":"4","author":"CM Lovly","year":"2014","unstructured":"Lovly, C. M. et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Disco. 4, 889\u2013895 (2014).","journal-title":"Cancer Disco."},{"key":"256_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S2213-2600(18)30116-4","volume":"6","author":"P Schoffski","year":"2018","unstructured":"Schoffski, P. et al. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. Lancet Respir. Med. 6, 431\u2013441 (2018).","journal-title":"Lancet Respir. Med."},{"key":"256_CR18","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1093\/annonc\/mdw405","volume":"27","author":"AS Mansfield","year":"2016","unstructured":"Mansfield, A. S. et al. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib. Ann. Oncol. 27, 2111\u20132117 (2016).","journal-title":"Ann. Oncol."},{"key":"256_CR19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1530\/ERC-19-0325","volume":"26","author":"F Panebianco","year":"2019","unstructured":"Panebianco, F. et al. Characterization of thyroid cancer driven by known and novel ALK fusions. Endocr. Relat. Cancer 26, 803\u2013814 (2019).","journal-title":"Endocr. Relat. Cancer"},{"key":"256_CR20","doi-asserted-by":"publisher","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-10-2956","volume":"70","author":"T Sasaki","year":"2010","unstructured":"Sasaki, T. et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 70, 10038\u201310043 (2010).","journal-title":"Cancer Res."},{"key":"256_CR21","doi-asserted-by":"publisher","first-page":"120ra117","DOI":"10.1126\/scitranslmed.3003316","volume":"4","author":"R Katayama","year":"2012","unstructured":"Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4, 120ra117 (2012).","journal-title":"Sci. Transl. Med."},{"key":"256_CR22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters, S. et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377, 829\u2013838 (2017).","journal-title":"N. Engl. J. Med."},{"key":"256_CR23","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","volume":"379","author":"DR Camidge","year":"2018","unstructured":"Camidge, D. R. et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 379, 2027\u20132039 (2018).","journal-title":"N. Engl. J. Med."},{"key":"256_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","volume":"21","author":"A Drilon","year":"2020","unstructured":"Drilon, A. et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 21, 261\u2013270 (2020).","journal-title":"Lancet Oncol."},{"key":"256_CR25","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw, A. T. et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 18, 1590\u20131599 (2017).","journal-title":"Lancet Oncol."},{"key":"256_CR26","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","volume":"20","author":"AT Shaw","year":"2019","unstructured":"Shaw, A. T. et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 20, 1691\u20131701 (2019).","journal-title":"Lancet Oncol."},{"key":"256_CR27","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","volume":"25","author":"R Benayed","year":"2019","unstructured":"Benayed, R. et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin. Cancer Res. 25, 4712\u20134722 (2019).","journal-title":"Clin. Cancer Res."},{"key":"256_CR28","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1200\/JCO.19.03010","volume":"38","author":"KT Flaherty","year":"2020","unstructured":"Flaherty, K. T. et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: national cancer institute molecular analysis for therapy choice (NCI-MATCH). J. Clin. Oncol. 38, 3883\u20133894 (2020).","journal-title":"J. Clin. Oncol."},{"key":"256_CR29","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/jnci\/djz245","volume":"112","author":"KT Flaherty","year":"2020","unstructured":"Flaherty, K. T. et al. The molecular analysis for therapy choice (NCI-MATCH) trial: lessons for genomic trial design. J. Natl Cancer Inst. 112, 1021\u20131029 (2020).","journal-title":"J. Natl Cancer Inst."},{"key":"256_CR30","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963\u20131972 (2010).","journal-title":"J. Clin. Oncol."},{"key":"256_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jmoldx.2016.10.007","volume":"19","author":"CJ Lih","year":"2017","unstructured":"Lih, C. J. et al. Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: molecular analysis for therapy choice clinical trial. J. Mol. Diagn. 19, 313\u2013327 (2017).","journal-title":"J. Mol. Diagn."},{"key":"256_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"256_CR33","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25, 579\u2013586 (2007).","journal-title":"J. Clin. Oncol."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00256-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00256-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00256-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T07:58:42Z","timestamp":1669363122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00256-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["256"],"URL":"https:\/\/doi.org\/10.1038\/s41698-022-00256-w","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"assertion":[{"value":"24 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mansfield: Direct research funding: Novartis, and Verily; Honoraria to institution for participation in advisory boards: AbbVie, BeiGene, BMS, Genentech, Inc., Janssen; Travel support: Roche, and non-remunerated member of the Mesothelioma Applied Research Foundation Board of Directors. Forde: Consultant\/Advisory boards: Abbvie, AstraZeneca, BMS, Janssen. Research Funding (to institution): AstraZeneca, BMS. Dr. Shaw has served as a compensated consultant or received honoraria from Achilles, Archer, Ariad\/Takeda, Bayer, Blueprint Medicines, Chugai, Daiichi-Sankyo, EMD Serono, Foundation Medicine, Guardant, Ignyta, KSQ Therapeutics, Loxo Oncology, Natera, Novartis, Pfizer, Roche-Genentech, Servier, Syros, Taiho Pharmaceutical, and TP Therapeutics; received institutional research funding from Ariad, Ignyta, Novartis, Pfizer, Roche-Genentech, and TP Therapeutics; received travel support from Genentech and Pfizer, and is currently employed by and owns stock in Novartis. Drilon: Honoraria\/Advisory Boards: Ignyta\/Genentech\/Roche, Loxo\/Bayer\/Lilly, Takeda\/Ariad\/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner\/Elevation Oncology, Remedica Ltd., ArcherDX, Monopteros, Novartis, EMD Serono, Melendi; Research to Institution: Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, PharmaMar; Royalties: Wolters Kluwer; OTHER: Merck, Puma, Merus, Boehringer Ingelheim. Hovelson: Equity holder and employee of Strata Oncology. Tomlins: Equity holder and employee of Strata Oncology. Named as co-inventors on a patent issued to Strata Oncology related to MSI status assessment. Named as co-inventor and included in royalty streams for a patent issued to the University of Michigan regarding ETS fusions in prostate cancer that has been licensed to Hologic\/Gen-Probe (sublicensed to Ventana Medical Systems) and LynxDx. Equity holder in Javelin Oncology. Previously served as a consultant to Strata Oncology and has consulted for Astellas\/Medivation and Janssen. He has received research (to the University of Michigan) funding from Astellas and has received travel support from the Prostate Cancer Foundation. Hamilton: Consultant\/Advisory Boards: Merck, Incyte, Bristol Myers Squibb, GSK, Loxo, Roche, Thermo Fisher Scientific, illmina, HalioDx. Research Funding to Institution: Guardant Health, CME: Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences. Arteaga: reported receiving grants from Lilly, Pfizer, and Takeda; serving in an expert advisory role to Novartis, Lilly, Immunomedics, Merck, Daiichi Sankyo, Taiho Oncology, AstraZeneca, and OrigiMed outside the submitted work; holding minor stock options in Y-TRAP and Provista, and serving in the Scientific Advisory Board of the Susan G. Komen Foundation. All remaining authors have declared no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}